215 related articles for article (PubMed ID: 37075513)
1. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
2. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
3. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
4. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Gibson D
J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
[TBL] [Abstract][Full Text] [Related]
5. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
6. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
7. Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.
Zhou Q; Chen S; Xu Z; Liu G; Zhang S; Wang Z; Tse MK; Yiu SM; Zhu G
Angew Chem Int Ed Engl; 2023 Apr; 62(18):e202302156. PubMed ID: 36878864
[TBL] [Abstract][Full Text] [Related]
8. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
9. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
10. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
11. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
12. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
[TBL] [Abstract][Full Text] [Related]
13. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
15. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes.
Bolitho EM; Sanchez-Cano C; Shi H; Quinn PD; Harkiolaki M; Imberti C; Sadler PJ
J Am Chem Soc; 2021 Dec; 143(48):20224-20240. PubMed ID: 34808054
[TBL] [Abstract][Full Text] [Related]
17. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity.
Aher S; Zhu J; Bhagat P; Borse L; Liu X
Top Curr Chem (Cham); 2024 Feb; 382(1):6. PubMed ID: 38400859
[TBL] [Abstract][Full Text] [Related]
18. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Specific, Intracellular, Reductive Activation of Anticancer Pt
Reshetnikov V; Daum S; Mokhir A
Chemistry; 2017 Apr; 23(24):5678-5681. PubMed ID: 28319647
[TBL] [Abstract][Full Text] [Related]
20. A safe and efficacious Pt(ii) anticancer prodrug: design, synthesis, in vitro efficacy, the role of carrier ligands and in vivo tumour growth inhibition.
Dutta PK; Sharma R; Kumari S; Dubey RD; Sarkar S; Paulraj J; Vijaykumar G; Pandey M; Sravanti L; Samarla M; Das HS; Yashpal ; B H; Goyal R; Gupta N; Mandal SK; Sengupta A; Sarkar A
Chem Commun (Camb); 2019 Feb; 55(12):1718-1721. PubMed ID: 30623966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
